Karyopharm Therapeutics (NASDAQ: KPTI) — Company Overview, News & Financial Data
Karyopharm Therapeutics develops first-in-class cancer drugs, leveraging proprietary technology to tackle unmet medical needs.
Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) focuses on the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other major diseases. With a keen emphasis on innovative therapeutic approaches, the company aims to tackle unmet medical needs, particularly in the oncology sector. Projects spearheaded by Karyopharm often revolve around the utilization of its proprietary SINE technology, designed to modulate nuclear export signals critical in cancer cell proliferation and survival. Their flagship product, selinexor, has made significant impacts in the treatment landscape for multiple myeloma and diffuse large B-cell lymphoma, marking strides towards achieving their objective of transforming cancer care. Through rigorous research and development, Karyopharm strives to expand its portfolio and impact across various cancer types, underscoring its commitment to advancing healthcare solutions.
Snapshot
Operations
Products and/or services of Karyopharm Therapeutics
- XPOVIO (selinexor) - First and only XPO1 inhibitor for multiple myeloma and diffuse large B-cell lymphoma.
- Clinical trials for selinexor in various cancer types - Expanding the potential use of selinexor in oncology.
- Eltanexor development - A second-generation SINE compound with potential for treating myelodysplastic syndromes.
- KPT-9274 - Dual PAK4/NAMPT inhibitor, focused on non-Hodgkin's lymphoma and solid tumors.
- Research on new SINE compounds - Innovating more selective inhibitors targeting the XPO1 cancer pathway.
- Partnerships for drug development and commercialization - Collaborating to enhance global reach and accelerate drug development pipelines.
Karyopharm Therapeutics executive team
- Richard A. PaulsonPresident, CEO & Director
- Stuart PoultonExecutive VP & Chief Development Officer
- Reshma RangwalaExecutive VP, Chief Medical Officer & Head of Research
- Sharon ShachamCo-Founder & Chairman of Scientific Advisory Board
- Lori A. MacomberEVP, CFO & Treasurer
- Kristin AbateVP, Chief Accounting Officer & Assistant Treasurer
- Brendan Twohig StrongSenior Vice President of Investor Relations
- Michael J. ManoExecutive VP, Chief Legal Officer & Secretary
- James AccumannoChief Compliance Officer
- Lisa DiPaoloExecutive VP & Chief Human Resource Officer
Latest news about Karyopharm Therapeutics
Karyopharm seeks XPOVIO myelofibrosis approval
United StatesKaryopharm bone marrowcancer combination selected for top EHA presentation
United StatesKaryopharm reports mixed Phase 3 SENTRY results in frontline myelofibrosis
United StatesKaryopharm eyes "transformative" 2026 with imminent Phase 3 data readouts
United States
Key financials
Reported results for Karyopharm Therapeutics, in USD.
- Market cap
- 2M
- Revenue (TTM)
- 146.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -14.3
- Dividend yield
- —
- Profit margin
- -153.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 146.1M | -90.7M | -196M | |
| 145.2M | -119.4M | -76.4M | |
| 146M | -129.5M | -143.1M | |
| 157.1M | -142.2M | -165.3M |